J Cancer 2020; 11(10):2749-2758. doi:10.7150/jca.37445

Review

Pancreatic Cancer, Gut Microbiota, and Therapeutic Efficacy

Xiang Zhang, Qiaofei Liu, Quan Liao, Yupei Zhao

Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Zhang X, Liu Q, Liao Q, Zhao Y. Pancreatic Cancer, Gut Microbiota, and Therapeutic Efficacy. J Cancer 2020; 11(10):2749-2758. doi:10.7150/jca.37445. Available from http://www.jcancer.org/v11p2749.htm

File import instruction

Abstract

Pancreatic cancer remains one of the leading causes of cancer-related death worldwide and has a poor prognosis. Current treatment relies on surgical resection and adjuvant therapies. The gut microbiota plays important roles in metabolism and immunomodulation. Accumulating evidence has implied that the gut microbiota is involved in the metabolism of chemotherapeutic drugs and the tumor microenvironment (TME), which could affect the efficacy of both conventional chemotherapy and immunotherapy for pancreatic cancer. Herein, we comprehensively reviewed the history and highlights of the interactions among pancreatic cancer, the gut microbiota and therapeutic efficacy and showed the promising future of manipulating the gut microbiota to improve clinical outcomes of pancreatic cancer.

Keywords: gut microbiota, pancreatic cancer, chemotherapy, immunotherapy, tumor microenvironment